



**Neuren Pharmaceuticals (NEU) – ASX Announcement**

**15 June 2021**

## **Neuren’s CEO Jon Pilcher appointed to board of directors**

**Melbourne, Australia:** Neuren Pharmaceuticals Limited (ASX: NEU) today reported that Chief Executive Officer Jon Pilcher has been appointed to Neuren’s board of directors as Managing Director, effective 14 June 2021. There are no changes to the terms of Jon’s employment agreement.

Neuren Chairman Patrick Davies commented: “On behalf of the Board, I am delighted with Jon’s appointment as Managing Director, which is a logical progression of his executive leadership role and underlines our shared commitment to deliver the value of Neuren’s late-stage development pipeline.”

### **About Neuren**

Neuren is developing two new drug therapies to treat multiple serious neurological disorders that emerge in early childhood, none of which have any approved medicines.

The lead drug compound, trofinetide, is currently in a Phase 3 clinical trial for Rett syndrome with top-line results expected in Q4 2021 and has completed a Phase 2 clinical trial in Fragile X syndrome. Both programs have been granted Fast Track designation by the US Food and Drug Administration (FDA). Neuren has granted an exclusive licence to ACADIA Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America.

Neuren is preparing to initiate Phase 2 trials of its second drug candidate, NNZ-2591, for each of Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome in H2 2021. Neuren is also planning a Phase 2 trial in Prader-Willi syndrome.

Because of the urgent unmet need, five programs have been granted “orphan drug” designation in both the United States and the European Union, a designation that provides incentives to encourage therapies for rare and serious diseases.

### **Contact:**

Jon Pilcher, CEO: [jpilcher@neurenpharma.com](mailto:jpilcher@neurenpharma.com); +61 438 422 271

### **Forward-looking Statements**

*This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.*



**ASX Listing Rules information**

This announcement was authorized to be given to the ASX by the board of directors of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124